Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology

Basit Öğe Kaydı
dc.contributor.authorAydin, Suna
dc.contributor.authorAydin, Suleyman
dc.contributor.authorKobat, Mehmet Ali
dc.contributor.authorKalayci, Mehmet
dc.contributor.authorEren, Mehmet Nesimi
dc.contributor.authorYilmaz, Musa
dc.contributor.authorKuloglu, Tuncay
dc.date.accessioned2024-04-24T16:15:48Z
dc.date.available2024-04-24T16:15:48Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractIrisin is a muscle-secreted protein. Cardiac muscle produces more irisin than skeletal muscle in response to acute exercise, and is associated with myocardial infarction (MI) in an experimental model induced by isoproterenol in rats. The timing and significance of its release in patients with acute myocardial infarction (AMI) needs further investigation. We have studied the relationship between serum/saliva irisin concentration and AMI in humans. Serum and saliva samples were taken within 3 days of admission in 11 patients with AMI and in 14 matched controls. Salivary gland irisin was detected immunohistochemically, and serum and saliva levels were measured by ELISA. The three major paired salivary glands (submandibular, sublingual and parotid) produce and release irisin into saliva. Troponin-I, CK, CK-MB concentrations in the AMI group gradually increased from up to 12 h, while saliva and serum irisin gradually decreased from up to 48 h, compared with the control group (P < 0.05). After 12 h, troponin-I, CK, CK-MB started to decrease, while saliva and serum irisin started to increase at 72 h. Serum irisin levels correlated with age, while troponin I, CK-MB, and CK were correlated and with saliva irisin in AMI patients. Besides cardiac troponin and CK-MB, irisin adds new diagnostic information in AMI patients, and the gradual decrease of saliva/serum irisin over 48 h could be a useful biomarker. (c) 2014 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.peptides.2014.04.002
dc.identifier.endpage145en_US
dc.identifier.issn0196-9781
dc.identifier.issn1873-5169
dc.identifier.pmid24747283
dc.identifier.scopus2-s2.0-84899553399
dc.identifier.scopusqualityQ2
dc.identifier.startpage141en_US
dc.identifier.urihttps://doi.org/10.1016/j.peptides.2014.04.002
dc.identifier.urihttps://hdl.handle.net/11468/15932
dc.identifier.volume56en_US
dc.identifier.wosWOS:000336521500018
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofPeptides
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIrisinen_US
dc.subjectMyocardial Infarctionen_US
dc.subjectSalivaen_US
dc.subjectSerumen_US
dc.titleDecreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathologyen_US
dc.titleDecreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu